Daily Archives: February 8, 2019

Etrolizumab, a monoclonal antibody to the β7 integrin, inhibits both α4β7:mucosal addressin cell adhesion molecule 1 (MAdCAM-1)–mediated lymphocyte trafficking to the gut mucosa and αEβ7:E-cadherin–mediated lymphocyte retention. In patients wi… Continue reading →

SHP647, a fully human IgG2 monoclonal antibody, binds to human mucosal addressin cell adhesion molecule-1 (MAdCAM-1) to reduce lymphocyte homing to the gastrointestinal tract. SHP647 was well tolerated in a randomized, double-blind phase 2 trial (TURAN… Continue reading →

The endothelial adhesion protein mucosal addressin cell adhesion molecule-1 (MAdCAM-1) is a promising novel drug target. The fully human IgG2 anti-MAdCAM-1 monoclonal antibody SHP647 is in development for the treatment of Crohn’s disease (CD). Continue reading →

There are several biologic therapies approved in Japan for moderate-to-severe ulcerative colitis (UC) but there are no head-to-head randomized controlled trials (RCTs) or network meta-analysis (NMA) for comparing their efficacy. We aimed to compare the… Continue reading →

Issues with patient recruitment and enrollment are the primary barriers for missed clinical trial timelines; 8 out of 10 clinical trials are delayed or unable to be completed because of lack of timely patient recruitment. Current patient recruitment ef… Continue reading →

Inflammatory bowel disease (IBD) is a chronic debilitating condition involving the gastrointestinal (GI) tract that has a negative impact on quality of life (QoL). Depressive symptoms (DS) are common in affected patients and contribute to decreased QoL… Continue reading →

A need exists for effective and safe oral therapeutic options for moderate to severe ulcerative colitis (UC). TD-1473 is an orally administered and gut-selective pan-Janus kinase (JAK) inhibitor that was well tolerated by healthy volunteers when admini… Continue reading →

Several alterations (dysbiosis) have been found in the gut microbial profile of UC patients including a decrease in diversity, Bifidobacterium and other some of commensal gut flora. Despite the impressive alterations in the gut microbiome of UC patient… Continue reading →

Fecal Microbiota Transplantation (FMT) is effective for the treatment of recurrent Clostridium difficile infection, but its efficacy for ulcerative colitis (UC) remains controversial. Ishikawa, et al reported that combination therapy with FMT and anti… Continue reading →

DEVELOP is a multicenter, prospective, observational registry of the long-term safety and clinical status of 6070 pediatric patients with inflammatory bowel disease (IBD; Crohn’s disease [CD]: 4122, ulcerative colitis [UC]: 1643, and IBD-unclassifie… Continue reading →